Hainan Shuangcheng Pharmaceuticals Performance dei guadagni passati
Il passato criteri di controllo 0/6
Hainan Shuangcheng Pharmaceuticals's earnings have been declining at an average annual rate of -25.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 8.8% per year.
Informazioni chiave
-25.9%
Tasso di crescita degli utili
-25.2%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 10.9% |
| Tasso di crescita dei ricavi | -8.8% |
| Rendimento del capitale proprio | -22.8% |
| Margine netto | -48.1% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2024 |
Aggiornamenti sulle prestazioni recenti
Ripartizione dei ricavi e delle spese
Come Hainan Shuangcheng Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 24 | 181 | -87 | 144 | 12 |
| 30 Jun 24 | 192 | -76 | 146 | 9 |
| 31 Mar 24 | 197 | -64 | 156 | 8 |
| 31 Dec 23 | 236 | -51 | 176 | 8 |
| 30 Sep 23 | 259 | 11 | 194 | 14 |
| 30 Jun 23 | 287 | 20 | 202 | 14 |
| 31 Mar 23 | 283 | 13 | 204 | 15 |
| 01 Jan 23 | 275 | 9 | 202 | 15 |
| 30 Sep 22 | 267 | -20 | 207 | 10 |
| 30 Jun 22 | 273 | -28 | 221 | 12 |
| 31 Mar 22 | 310 | -16 | 249 | 9 |
| 01 Jan 22 | 320 | -20 | 265 | 11 |
| 30 Sep 21 | 330 | -32 | 279 | 11 |
| 30 Jun 21 | 329 | -30 | 280 | 10 |
| 31 Mar 21 | 300 | -51 | 266 | 13 |
| 31 Dec 20 | 269 | -53 | 245 | 12 |
| 30 Sep 20 | 267 | 21 | 231 | -2 |
| 30 Jun 20 | 283 | 22 | 248 | 2 |
| 31 Mar 20 | 321 | 28 | 268 | 7 |
| 31 Dec 19 | 347 | 25 | 274 | 13 |
| 30 Sep 19 | 348 | -59 | 295 | 28 |
| 30 Jun 19 | 338 | -65 | 264 | 25 |
| 31 Mar 19 | 320 | -75 | 255 | 20 |
| 31 Dec 18 | 337 | -69 | 261 | 15 |
| 30 Sep 18 | 345 | -17 | 251 | 15 |
| 30 Jun 18 | 347 | 5 | 239 | 20 |
| 31 Mar 18 | 300 | 12 | 191 | 18 |
| 31 Dec 17 | 247 | 6 | 160 | 15 |
| 30 Sep 17 | 205 | -175 | -3 | 10 |
| 30 Jun 17 | 167 | -386 | 173 | 0 |
| 31 Mar 17 | 167 | -386 | 181 | 0 |
| 31 Dec 16 | 145 | -388 | 173 | 0 |
| 30 Sep 16 | 198 | -208 | 296 | 0 |
| 30 Jun 16 | 198 | 11 | 84 | 0 |
| 31 Mar 16 | 224 | 37 | 78 | 0 |
| 31 Dec 15 | 231 | 53 | 68 | 0 |
| 30 Sep 15 | 186 | 60 | 52 | 0 |
| 30 Jun 15 | 179 | 56 | 60 | 0 |
| 31 Mar 15 | 165 | 60 | 49 | 0 |
| 31 Dec 14 | 161 | 61 | 49 | 0 |
| 30 Sep 14 | 162 | 61 | 48 | 0 |
| 30 Jun 14 | 151 | 63 | 42 | 0 |
| 31 Mar 14 | 147 | 66 | 40 | 0 |
| 31 Dec 13 | 150 | 67 | 39 | 0 |
Guadagni di qualità: 002693 is currently unprofitable.
Margine di profitto in crescita: 002693 is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 002693 is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.
Accelerare la crescita: Unable to compare 002693's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: 002693 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Rendimento del capitale proprio
ROE elevato: 002693 has a negative Return on Equity (-22.76%), as it is currently unprofitable.